Because the zinc LIV-1(SLC39A6) transporter is expressed in all breast cancer subtypes, Seattle Genetics constructed a novel antibody-drug conjugate, SGN-LIV1A, targeting LIV-1 for the treatment of metastatic breast cancer122. Here, SLC39A6 is linked to breast cancer.